Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2964595 | 0.87 | LTA4H (0.49) | LTA4HNPC1RAB9AGRIN1GRIN2B | |
| SCHEMBL6150612 | 0.84 | KDM4E (0.43) | LTA4HKDM4EALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL4134193 | 0.82 | KCNH2 (0.53) | KDM4EALDH1A1MEN1KCNH2KCNA5 | |
| SCHEMBL4145069 | 0.80 | KDM4E (0.64) | LTA4HNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL4137801 | 0.77 | KCNH2 (0.59) | MEN1KCNH2 | |
| SCHEMBL4669237 | 0.76 | KCNH2 (0.52) | KDM4EALDH1A1SMN1; SMN2MEN1KCNH2 | |
| SCHEMBL1619409 | 0.76 | KCNH2 (0.54) | MEN1KCNH2KCNA5 | |
| SCHEMBL4669159 | 0.75 | KCNH2 (0.49) | MEN1KCNH2KCNA5 | |
| SCHEMBL4139633 | 0.75 | KCNH2 (0.53) | KDM4EALDH1A1MEN1KMT2AKCNH2 | |
| SCHEMBL3123059 | 0.73 | KCNH2 (0.60) | LTA4HKCNH2KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| EP-1235831-B1 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-03-30 | — | — | EP | claimed |
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-1893619-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTMIAS | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006135316-A1 | New oxabispidine compounds for the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | WO | disclosed |
| EP-1503782-A1 | A COMBINATION PRODUCT COMPRISING MELAGATRAN AND AN ANTI-ARRHYTHMIC OXABISPIDENES | AstraZeneca AB (SE) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003092721-A1 | A COMBINATION PRODUCT COMPRISING MELAGATRAN AND AN ANTI-ARRHYTHMIC OXABISPIDENES | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054422-A1 | New Oxabispidine Compounds For The Treatment Of Cardiac Arrhythmias | RYR1, KCNH1, CACNA1E | LTA4H 3753/4885NPC1 3603/4885RAB9A 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.